# Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer

> **NCT02768701** · PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02768701
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-18
- **Primary completion:** 2022-05-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02768701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02768701, "Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02768701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*